123 related articles for article (PubMed ID: 27497829)
1. Trastuzumab Emtansine in HER2+ Recurrent Metastatic Non-Small-Cell Lung Cancer: Study Protocol.
Ohashi K; Hotta K; Hirata T; Aoe K; Kozuki T; Ninomiya K; Kayatani H; Yanai H; Toyooka S; Hinotsu S; Takata M; Kiura K
Clin Lung Cancer; 2017 Jan; 18(1):92-95. PubMed ID: 27497829
[TBL] [Abstract][Full Text] [Related]
2. Relationship between HER2 expression and efficacy with first-line trastuzumab emtansine compared with trastuzumab plus docetaxel in TDM4450g: a randomized phase II study of patients with previously untreated HER2-positive metastatic breast cancer.
Perez EA; Hurvitz SA; Amler LC; Mundt KE; Ng V; Guardino E; Gianni L
Breast Cancer Res; 2014 May; 16(3):R50. PubMed ID: 24887458
[TBL] [Abstract][Full Text] [Related]
3. Responses to subsequent anti-HER2 therapy after treatment with trastuzumab-DM1 in women with HER2-positive metastatic breast cancer.
Olson EM; Lin NU; DiPiro PJ; Najita JS; Krop IE; Winer EP; Burstein HJ
Ann Oncol; 2012 Jan; 23(1):93-97. PubMed ID: 21531783
[TBL] [Abstract][Full Text] [Related]
4. Superior in vitro and in vivo activity of trastuzumab-emtansine (T-DM1) in comparison to trastuzumab, pertuzumab and their combination in epithelial ovarian carcinoma with high HER2/neu expression.
Menderes G; Bonazzoli E; Bellone S; Altwerger G; Black JD; Dugan K; Pettinella F; Masserdotti A; Riccio F; Bianchi A; Zammataro L; de Haydu C; Buza N; Hui P; Wong S; Huang GS; Litkouhi B; Ratner E; Silasi DA; Azodi M; Schwartz PE; Santin AD
Gynecol Oncol; 2017 Oct; 147(1):145-152. PubMed ID: 28705408
[TBL] [Abstract][Full Text] [Related]
5. Effects of trastuzumab emtansine on canine urothelial carcinoma cells in vitro and in vivo.
Sakai K; Kato D; Yoshinaka J; Takahashi Y; Ikeda N; Aoki S; Iguchi T; Ishikawa S; Yamagishi N; Shimamura S; Nakagawa T
Vet Comp Oncol; 2024 Jun; 22(2):230-238. PubMed ID: 38502572
[TBL] [Abstract][Full Text] [Related]
6. Activity of T-DM1 in HER-2 positive central nervous system breast cancer metastases.
Torres S; Maralani P; Verma S
BMJ Case Rep; 2014 Aug; 2014():. PubMed ID: 25123575
[TBL] [Abstract][Full Text] [Related]
7. Serum level of hepatocyte growth factor is a novel marker of predicting the outcome and resistance to the treatment with trastuzumab in HER2-positive patients with metastatic gastric cancer.
Takahashi N; Furuta K; Taniguchi H; Sasaki Y; Shoji H; Honma Y; Iwasa S; Okita N; Takashima A; Kato K; Hamaguchi T; Shimada Y; Yamada Y
Oncotarget; 2016 Jan; 7(4):4925-38. PubMed ID: 26716644
[TBL] [Abstract][Full Text] [Related]
8. Metastatic
Yun KM; Bazhenova L
BMJ Case Rep; 2023 May; 16(5):. PubMed ID: 37156567
[TBL] [Abstract][Full Text] [Related]
9. Prevalence and Therapeutic Targeting of High-Level ERBB2 Amplification in NSCLC.
Odintsov I; Makarem M; Nishino M; Bachert SE; Zhang T; LoPiccolo J; Paweletz CP; Gokhale PC; Ivanova E; Saldanha A; Rudin CM; Lockwood WW; Ladanyi M; Somwar R; Jänne PA; Sholl LM
J Thorac Oncol; 2024 May; 19(5):732-748. PubMed ID: 38154514
[TBL] [Abstract][Full Text] [Related]
10. A phase 2 trial of zanidatamab in HER2-overexpressed advanced endometrial carcinoma and carcinosarcoma (ZW25-IST-2).
Lumish M; Chui MH; Zhou Q; Iasonos A; Sarasohn D; Cohen S; Friedman C; Grisham R; Konner J; Kyi C; Rubinstein M; Troso-Sandoval T; Aghajanian C; Makker V
Gynecol Oncol; 2024 Mar; 182():75-81. PubMed ID: 38262242
[TBL] [Abstract][Full Text] [Related]
11. The application of HER2-ADC in future: More than expression.
Zhou J; He H; Wang S; Li N
Med; 2024 Mar; 5(3):173-175. PubMed ID: 38460494
[TBL] [Abstract][Full Text] [Related]
12. [Trastuzumab-deruxtecan monotherapy in HER2-activated advanced non-small cell lung cancer pre-treated with platinum-based chemotherapy with or without immunotherapy].
Rivier C; Lavaud P
Bull Cancer; 2024 Mar; ():. PubMed ID: 38553285
[No Abstract] [Full Text] [Related]
13. A Phase II Study of Trastuzumab Emtansine in HER2-Positive Non-Small Cell Lung Cancer.
Hotta K; Aoe K; Kozuki T; Ohashi K; Ninomiya K; Ichihara E; Kubo T; Ninomiya T; Chikamori K; Harada D; Nogami N; Hirata T; Hinotsu S; Toyooka S; Kiura K
J Thorac Oncol; 2018 Feb; 13(2):273-279. PubMed ID: 29313813
[TBL] [Abstract][Full Text] [Related]
14. Phase II Study of the EGFR-TKI Rechallenge With Afatinib in Patients With Advanced NSCLC Harboring Sensitive EGFR Mutation Without T790M: Okayama Lung Cancer Study Group Trial OLCSG 1403.
Oda N; Ichihara E; Hotta K; Ninomiya K; Ninomiya T; Kubo T; Minami D; Murakami T; Yokoyama T; Harada D; Kuyama S; Ichikawa H; Inoue K; Kishino D; Inoue M; Takigawa N; Shibayama T; Harita S; Tanimoto M; Kiura K
Clin Lung Cancer; 2017 Mar; 18(2):241-244. PubMed ID: 27506489
[TBL] [Abstract][Full Text] [Related]
15. Trastuzumab emtansine suppresses the growth of HER2-positive small-cell lung cancer in preclinical models.
Morimura O; Minami T; Kijima T; Koyama S; Otsuka T; Kinehara Y; Osa A; Higashiguchi M; Miyake K; Nagatomo I; Hirata H; Iwahori K; Takimoto T; Takeda Y; Kida H; Kumanogoh A
Biochem Biophys Res Commun; 2017 Jul; 488(4):596-602. PubMed ID: 28526406
[TBL] [Abstract][Full Text] [Related]
16. A phase II study of topotecan and cisplatin with sequential thoracic radiotherapy in elderly patients with small-cell lung cancer: Okayama Lung Cancer Study Group 0102.
Kubo T; Fujiwara K; Hotta K; Okada T; Kuyama S; Harita S; Ninomiya T; Kamei H; Hosokawa S; Bessho A; Maeda T; Kozuki T; Fujimoto N; Ninomiya K; Takemoto M; Kanazawa S; Takigawa N; Tabata M; Tanimoto M; Ueoka H; Kiura K
Cancer Chemother Pharmacol; 2016 Oct; 78(4):769-74. PubMed ID: 27544764
[TBL] [Abstract][Full Text] [Related]
17. ERBB2-Mutated Metastatic Non-Small Cell Lung Cancer: Response and Resistance to Targeted Therapies.
Chuang JC; Stehr H; Liang Y; Das M; Huang J; Diehn M; Wakelee HA; Neal JW
J Thorac Oncol; 2017 May; 12(5):833-842. PubMed ID: 28167203
[TBL] [Abstract][Full Text] [Related]
18. HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium.
Pillai RN; Behera M; Berry LD; Rossi MR; Kris MG; Johnson BE; Bunn PA; Ramalingam SS; Khuri FR
Cancer; 2017 Nov; 123(21):4099-4105. PubMed ID: 28743157
[TBL] [Abstract][Full Text] [Related]
19. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
Soria JC; Ohe Y; Vansteenkiste J; Reungwetwattana T; Chewaskulyong B; Lee KH; Dechaphunkul A; Imamura F; Nogami N; Kurata T; Okamoto I; Zhou C; Cho BC; Cheng Y; Cho EK; Voon PJ; Planchard D; Su WC; Gray JE; Lee SM; Hodge R; Marotti M; Rukazenkov Y; Ramalingam SS;
N Engl J Med; 2018 Jan; 378(2):113-125. PubMed ID: 29151359
[TBL] [Abstract][Full Text] [Related]
20. Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers.
Peters S; Stahel R; Bubendorf L; Bonomi P; Villegas A; Kowalski DM; Baik CS; Isla D; Carpeno JC; Garrido P; Rittmeyer A; Tiseo M; Meyenberg C; de Haas S; Lam LH; Lu MW; Stinchcombe TE
Clin Cancer Res; 2019 Jan; 25(1):64-72. PubMed ID: 30206164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
